Chronic Kidney Disease (Chronic Renal Failure) - Pipeline Review, H2 2011

Chronic Kidney Disease (Chronic Renal Failure) - Pipeline Review, H2 2011

Summary

Global Markets Direct’s, 'Chronic Kidney Disease (Chronic Renal Failure) - Pipeline Review, H2 2011', provides an overview of the Chronic Kidney Disease (Chronic Renal Failure) therapeutic pipeline. This report provides information on the therapeutic development for Chronic Kidney Disease (Chronic Renal Failure), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Chronic Kidney Disease (Chronic Renal Failure). 'Chronic Kidney Disease (Chronic Renal Failure) - Pipeline Review, H2 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Chronic Kidney Disease (Chronic Renal Failure).
- A review of the Chronic Kidney Disease (Chronic Renal Failure) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Chronic Kidney Disease (Chronic Renal Failure) pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Chronic Kidney Disease (Chronic Renal Failure).
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Chronic Kidney Disease (Chronic Renal Failure) pipeline depth and focus of Chronic Kidney Disease (Chronic Renal Failure) therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. SHOW LESS READ MORE >

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Chronic Kidney Disease (Chronic Renal Failure) Overview
Therapeutics Development
An Overview of Pipeline Products for Chronic Kidney Disease (Chronic Renal Failure)
Chronic Kidney Disease (Chronic Renal Failure) Therapeutics under Development by Companies
Chronic Kidney Disease (Chronic Renal Failure) Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Chronic Kidney Disease (Chronic Renal Failure) Therapeutics - Products under Development by Companies
Chronic Kidney Disease (Chronic Renal Failure) Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Chronic Kidney Disease (Chronic Renal Failure) Therapeutics Development
F. Hoffmann-La Roche Ltd.
Abbott Laboratories
Amgen Inc.
Eli Lilly and Company
Quark Pharmaceuticals, Inc.
Merck & Co., Inc.
MD Scientific, LLC
Astellas Pharma Inc.
Mitsubishi Tanabe Pharma Corporation
Pfizer Inc.
Nile Therapeutics, Inc.
Compugen Ltd.
Spectrum Pharmaceuticals, Inc.
Ocera Therapeutics, Inc.
Proteon Therapeutics, Inc.
Hawthorn Pharmaceuticals, Inc.
Promedior, Inc.
Reata Pharmaceuticals, Inc.
Thrasos, Inc.
Concert Pharmaceuticals, Inc.
CorMedix, Inc.
Vitae Pharmaceuticals, Inc.
KAI Pharmaceuticals Inc.
Stelic Institute & Co.
Sorbent Therapeutics, Inc.
InVasc Therapeutics, Inc.
Iperboreal Pharma srl
Chronic Kidney Disease (Chronic Renal Failure) - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Late Stage Drug Profiles
Aranesp - Drug Profile
Product Description
Mechanism of Action
R&D Progress
YM533 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MCI-196 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Bardoxolone Methyl - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AST-120 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Sodium Bicarbonate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CLP 1002 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Pentoxifylline - Drug Profile
Product Description
Mechanism of Action
R&D Progress
N-Acetylcysteine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Everolimus - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Benazepril - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Valsartan - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Benazepril + Valsartan - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Heparin Sodium - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Folate + Pyridoxine + Cyanocobalamin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Renagel + Cinacalcet - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Irbesartan - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CRMD-001 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Ramipril + Telmisartan - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Dextromethorphan + Silymarin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
N-Acetylcysteine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Paricalcitol - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Chronic Kidney Disease (Chronic Renal Failure) Therapeutics – Drug Profile Updates
Chronic Kidney Disease (Chronic Renal Failure) Therapeutics - Discontinued Products
Chronic Kidney Disease (Chronic Renal Failure) - Featured News
Sep 19, 2011: Keryx Completes Patient Enrollment In Zerenex Phase III Long-Term Study
Sep 06, 2011: Hospira Announces Positive Results From Phase I US Clinical Trial Of Biosimilar Erythropoietin In Renal Patients
Jul 27, 2011: Affymax And Takeda Announce FDA Acceptance Of New Drug Application For Peginesatide
Jun 28, 2011: Relypsa Begins Treatment In AMETHYST-DN Trial Of RLY5016 For Hyperkalemia In Diabetic Nephropathy Patients With Chronic Kidney Disease
Jun 27, 2011: Vitae Reports Positive Phase I Clinical Data In Chronic Kidney Disease Program At American Diabetes Association's 71st Scientific Sessions
Jun 24, 2011: Abbott Announces New Encouraging Phase II Data Of Bardoxolone Methyl Published In New England Journal Of Medicine
Jun 24, 2011: InVasc Initiates Phase IIa Proof Of Concept Study Of INV-144 In Patients With Chronic Kidney Disease
Jun 23, 2011: Akebia Initiates Phase IIa Dose Range Finding Study Of AKB-6548 In Anemia
Jun 21, 2011: CorMedix Announces SPA Agreement With FDA For Phase III Trial Of CRMD001 Study In Prevention Of CI-AKI
Jun 21, 2011: AMAG Pharmaceuticals Provides Update On Feraheme Label
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Chronic Kidney Disease (Chronic Renal Failure), H2 2011
Products under Development for Chronic Kidney Disease (Chronic Renal Failure) – Comparative Analysis, H2 2011
Number of Products under Development by Companies, H2 2011
Number of Products under Development by Companies, H2 2011
Number of Products under Investigation by Universities/Institutes, H2 2011
Number of Products under Investigation by Universities/Institutes, H2 2011
Comparative Analysis by Late Stage Development, H2 2011
Comparative Analysis by Mid Clinical Stage Development, H2 2011
Comparative Analysis by Early Clinical Stage Development, H2 2011
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2011
Products under Development by Companies, H2 2011
Products under Development by Companies, H2 2011
Products under Development by Companies, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
F. Hoffmann-La Roche Ltd., H2 2011
Abbott Laboratories, H2 2011
Amgen Inc., H2 2011
Eli Lilly and Company, H2 2011
Quark Pharmaceuticals, Inc., H2 2011
Merck & Co., Inc., H2 2011
MD Scientific, LLC, H2 2011
Astellas Pharma Inc., H2 2011
Mitsubishi Tanabe Pharma Corporation, H2 2011
Pfizer Inc., H2 2011
Nile Therapeutics, Inc., H2 2011
Compugen Ltd., H2 2011
Spectrum Pharmaceuticals, Inc., H2 2011
Ocera Therapeutics, Inc., H2 2011
Proteon Therapeutics, Inc., H2 2011
Hawthorn Pharmaceuticals, Inc., H2 2011
Promedior, Inc., H2 2011
Reata Pharmaceuticals, Inc., H2 2011
Thrasos, Inc., H2 2011
Concert Pharmaceuticals, Inc., H2 2011
CorMedix, Inc., H2 2011
Vitae Pharmaceuticals, Inc., H2 2011
KAI Pharmaceuticals Inc., H2 2011
Stelic Institute & Co., H2 2011
Sorbent Therapeutics, Inc., H2 2011
InVasc Therapeutics, Inc., H2 2011
Iperboreal Pharma srl, H2 2011
Assessment by Monotherapy Products, H2 2011
Assessment by Combination Products
Assessment by Stage and Route of Administration, H2 2011
Assessment by Molecule Type, H2 2011
Chronic Kidney Disease (Chronic Renal Failure) Therapeutics – Drug Profile Updates
Discontinued Products

List of Figures
Number of Products under Development for Chronic Kidney Disease (Chronic Renal Failure), H2 2011
Products under Development for Chronic Kidney Disease (Chronic Renal Failure) – Comparative Analysis, H2 2011
Products under Development by Companies, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Late Stage Products, H2 2011
Mid Clinical Stage Products, H2 2011
Early Clinical Stage Products, H2 2011
Discovery and Pre-Clinical Stage Products, H2 2011
Assessment by Monotherapy Products, H2 2011
Assessment by Combination Products, H2 2011
Assessment by Route of Administration, H2 2011
Assessment by Stage and Route of Administration, H2 2011
Assessment by Molecule Type, H2 2011
Assessment by Stage and Molecule Type, H2 2011